New Media Department            Yu Jie , Duan Yuqing            June 25, 2023

On June 19, Lunan Pharmaceutical Group Shandong New Time Pharmaceutical Co., Ltd. received the marketing authorization of sevoflurane for inhalation issued by the Netherlands Committee for Drug Evaluation (CBG) (certificate number: RVG 129198), marking that this product is allowed to enter the EU market , which is the second preparation product approved by Lunan Pharmaceutical Group in the Netherlands after Ezetimibe Tablets was launched in the Netherlands.

Lunan Pharmaceutical Group submitted an application for the registration of sevoflurane for inhalation through the DCP procedure on October 30, 2021, and ended the DCP procedure in May 2023, entering the national review stage in the Netherlands, Germany and Spain. With the approval of the main review country, the Netherlands, it is expected that Germany and Spain will issue marketing authorization for this product within 1 to 2 months.

Sevoflurane for inhalation is an anesthetic for inhalation, suitable for the induction and maintenance of general anesthesia in in-hospital and outpatient operations for adults and pediatric patients. Sevoflurane has the advantages of fast onset of action, short duration of action, easy adjustment of anesthesia depth, low incidence of nausea and vomiting, and relatively safe metabolites, which can bring patients a better surgical experience.